Abstract 532P
Background
Glioblastoma is the most common and aggressive type of primary brain tumor, with a high morbidity and mortality rate. Nitric oxide (NO) has been shown to have diverse effects on various cancers, including glioblastoma. Nitric oxide synthase (NOS) activation has been implicated in the growth and progression of glioblastoma. In this study, we investigated the effects of our novel two drugs HU-53 and HU-54, on the U87-MG cell line and a xenograft model of glioblastoma. Both drugs attenuate nitrative stress through different mechanisms.
Methods
NOD.CB17-Prkdc-scid/NCrHsd mice were used for the xenograft subcutaneous tumor model to evaluate the ability of HU-53 and HU-54 treatment regimens. Both treatments were given intraperitoneally. Tumor weight and volume were measured during the study. The experiments were also carried out on the human-derived U87-MG cells. Nitrite content was measured biochemically by Griess assay. Immunofluorescence and immunoblotting assessed nitrosative stress.
Results
We found that treatment with the combo-drug resulted in a significant decrease (P<0.0001) in cell viability and proliferation as compared to vehicle in the U87-MG cell line. The combo-drug also induced apoptosis as evidenced by increased caspase-3 activity. In addition, treatment with HU-53 and HU-54 resulted in a significant reduction (p<0.0001) in tumor growth in the xenograft model of glioblastoma, as demonstrated by decreased tumor volume and weight. Furthermore, we observed that the combo treatment resulted in a significant decrease in the level of nitrite content (p<0.02) and 3-Nitrotyrosine (a marker of nitrosative stress) which are important mediators of glioblastoma growth.
Conclusions
Our results suggest that targeting the nitrosative stress with HU-53 and HU-54 may be a promising therapeutic strategy for glioblastoma treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Hebrew University of Jerusalem.
Funding
The Hebrew University of Jerusalem, Israel.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Artificial intelligence-powered analysis of tumor lymphocytes infiltration: A translational analysis of AtezoTRIBE trial
Presenter: Martina Carullo
Session: Poster session 10
572P - Neoantigen heterogeneity among subtypes in colorectal cancer
Presenter: Fuqiang Li
Session: Poster session 10
574P - Comparative analysis of the tumor immune microenvironment (TIME) in primary and metastatic sites of microsatellite stable (MSS) and microsatellite instability-high (MSI) colorectal cancer
Presenter: Marwan Fakih
Session: Poster session 10
575P - Impact of immunological alterations and post-operative biomarkers on long-term outcomes in patients with locally advanced rectal cancer: Results from the STAR-01 study cohort
Presenter: Francesca Negri
Session: Poster session 10
576P - Prognostic values of a modified diagnostic biopsy-adapted immunoscore based on double immunohistochemical staining in patients with locally advanced rectal cancer
Presenter: Qiang Zeng
Session: Poster session 10
577P - Systematically assessing the intratissue microbiota in 937 patients with colorectal cancer
Presenter: Huanzi Zhong
Session: Poster session 10
578P - Tissue-resident microbiota characterization in colorectal cancer metastases
Presenter: Philippe Stevens
Session: Poster session 10
579P - A clinico-imaging predictive artificial intelligence model of relapse in colon cancer using baseline CT scans
Presenter: América Bueno Gómez
Session: Poster session 10
580P - Prognosis in stage II colorectal cancer: The effect of the primary tumor location and biomarkers
Presenter: Vincent Liégeois
Session: Poster session 10